Literature DB >> 24841978

Hispanic accrual on randomized cancer clinical trials: a call to arms.

Alberto Parra1, Anand B Karnad1, Ian M Thompson2.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24841978      PMCID： PMC4050202          DOI： 10.1200/JCO.2013.51.7946

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  21 in total

1.  Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy.

Authors:  Thomas S Uldrick; Kathleen M Wyvill; Pallavi Kumar; Deirdre O'Mahony; Wendy Bernstein; Karen Aleman; Mark N Polizzotto; Seth M Steinberg; Stefania Pittaluga; Vickie Marshall; Denise Whitby; Richard F Little; Robert Yarchoan
Journal:  J Clin Oncol       Date:  2012-03-19       Impact factor: 44.544

2.  Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer.

Authors:  Beth Y Karlan; Amit M Oza; Gary E Richardson; Diane M Provencher; Vincent L Hansen; Martin Buck; Setsuko K Chambers; Prafull Ghatage; Charles H Pippitt; John V Brown; Allan Covens; Raj V Nagarkar; Margaret Davy; Charles A Leath; Hoa Nguyen; Daniel E Stepan; David M Weinreich; Marjan Tassoudji; Yu-Nien Sun; Ignace B Vergote
Journal:  J Clin Oncol       Date:  2011-12-19       Impact factor: 44.544

3.  Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047.

Authors:  Alexandra M Levine; Ariela Noy; Jeannette Y Lee; Wayne Tam; Juan Carlos Ramos; David H Henry; Samir Parekh; Erin G Reid; Ronald Mitsuyasu; Timothy Cooley; Bruce J Dezube; Lee Ratner; Ethel Cesarman; Anil Tulpule
Journal:  J Clin Oncol       Date:  2012-11-19       Impact factor: 44.544

4.  Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

Authors:  Thomas J Lynch; Igor Bondarenko; Alexander Luft; Piotr Serwatowski; Fabrice Barlesi; Raju Chacko; Martin Sebastian; Joel Neal; Haolan Lu; Jean-Marie Cuillerot; Martin Reck
Journal:  J Clin Oncol       Date:  2012-04-30       Impact factor: 44.544

5.  International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.

Authors:  Giorgio V Scagliotti; Ihor Vynnychenko; Keunchil Park; Yukito Ichinose; Kaoru Kubota; Fiona Blackhall; Robert Pirker; Rinat Galiulin; Tudor-Eliade Ciuleanu; Oleksandr Sydorenko; Mircea Dediu; Zsolt Papai-Szekely; Natividad Martinez Banaclocha; Sheryl McCoy; Bin Yao; Yong-Jiang Hei; Francesco Galimi; David R Spigel
Journal:  J Clin Oncol       Date:  2012-07-02       Impact factor: 44.544

6.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Authors:  Jeffrey A Sosman; Kevin B Kim; Lynn Schuchter; Rene Gonzalez; Anna C Pavlick; Jeffrey S Weber; Grant A McArthur; Thomas E Hutson; Stergios J Moschos; Keith T Flaherty; Peter Hersey; Richard Kefford; Donald Lawrence; Igor Puzanov; Karl D Lewis; Ravi K Amaravadi; Bartosz Chmielowski; H Jeffrey Lawrence; Yu Shyr; Fei Ye; Jiang Li; Keith B Nolop; Richard J Lee; Andrew K Joe; Antoni Ribas
Journal:  N Engl J Med       Date:  2012-02-23       Impact factor: 91.245

Review 7.  Inclusion of minorities and women in cancer clinical trials, a decade later: Have we improved?

Authors:  Kat Kwiatkowski; Kathryn Coe; John C Bailar; G Marie Swanson
Journal:  Cancer       Date:  2013-05-14       Impact factor: 6.860

8.  L-carnitine supplementation for the management of fatigue in patients with cancer: an eastern cooperative oncology group phase III, randomized, double-blind, placebo-controlled trial.

Authors:  Ricardo A Cruciani; Jenny J Zhang; Judith Manola; David Cella; Bilal Ansari; Michael J Fisch
Journal:  J Clin Oncol       Date:  2012-09-17       Impact factor: 44.544

9.  Cancer statistics for Hispanics/Latinos, 2012.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2012 Sep-Oct       Impact factor: 508.702

10.  Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer.

Authors:  Luis G Paz-Ares; Bonne Biesma; David Heigener; Joachim von Pawel; Timothy Eisen; Jaafar Bennouna; Li Zhang; Meilin Liao; Yan Sun; Steven Gans; Kostas Syrigos; Etienne Le Marie; Maya Gottfried; Johan Vansteenkiste; Vincente Alberola; Uwe Phillip Strauss; Elaine Montegriffo; Teng Jin Ong; Armando Santoro
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544
View more
  13 in total

1.  Motivators and barriers to Latinas' participation in clinical trials: the role of contextual factors.

Authors:  Laricca London; Alejandra Hurtado-de-Mendoza; Minna Song; Ankita Nagirimadugu; Gheorghe Luta; Vanessa B Sheppard
Journal:  Contemp Clin Trials       Date:  2014-11-26       Impact factor: 2.226

2.  Educating Hispanics About Clinical Trials and Biobanking.

Authors:  M Lizette Rangel; Natalia I Heredia; Belinda Reininger; Lorna McNeill; Maria E Fernandez
Journal:  J Cancer Educ       Date:  2019-12       Impact factor: 2.037

3.  Discordant attitudes and beliefs about cancer clinical trial participation between physicians, research staff, and cancer patients.

Authors:  Grace C Hillyer; Melissa Beauchemin; Dawn L Hershman; Moshe Kelsen; Frances L Brogan; Rossy Sandoval; Karen M Schmitt; Andria Reyes; Mary Beth Terry; Andrew B Lassman; Gary K Schwartz
Journal:  Clin Trials       Date:  2020-02-03       Impact factor: 2.486

4.  Genomic Disparities in Breast Cancer Among Latinas.

Authors:  Filipa Lynce; Kristi D Graves; Lina Jandorf; Charite Ricker; Eida Castro; Laura Moreno; Bianca Augusto; Laura Fejerman; Susan T Vadaparampil
Journal:  Cancer Control       Date:  2016-10       Impact factor: 3.302

5.  Underrepresentation of Hispanics and Other Minorities in Clinical Trials: Recruiters' Perspectives.

Authors:  Aurora Occa; Susan E Morgan; JoNell E Potter
Journal:  J Racial Ethn Health Disparities       Date:  2017-04-27

6.  Engaging Latinos in an Academic-Community Partnership in Montana through a Health Screening Event.

Authors:  Sally C Moyce; Nathaniel Sisson; Sophia Thompson; Maria Velazqueaz; David Claudio; Elizabeth Aghbashian; Heather Demorest; Karl Vanderwood
Journal:  Am J Health Educ       Date:  2021-02-17

7.  Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study.

Authors:  Nefertiti C duPont; Danielle Enserro; Mark F Brady; Katherine Moxley; Joan L Walker; Casey Cosgrove; Kristin Bixel; Krishnansu S Tewari; Premal Thaker; Andrea E Wahner Hendrickson; Stephen Rubin; Keiichi Fujiwara; A Catherine Casey; John Soper; Robert A Burger; Bradley J Monk
Journal:  Gynecol Oncol       Date:  2021-11-29       Impact factor: 5.304

8.  Clinical trial awareness: Changes over time and sociodemographic disparities.

Authors:  Amanda Leiter; Michael A Diefenbach; John Doucette; William K Oh; Matthew D Galsky
Journal:  Clin Trials       Date:  2015-02-10       Impact factor: 2.486

9.  Knowledge, Motivations and Concerns about Participation in Breast Cancer Clinical Trials in Puerto Rico.

Authors:  Marinilda Rivera-Díaz; Angélica N García-Romero; Alelí M Ayala-Marín; Camille Vélez-Alamo; Adrianna I Acevedo-Fontánez; Mariana Arévalo; Vivian Colón-López
Journal:  J Health Dispar Res Pract       Date:  2020

10.  Mexican-American perspectives on participation in clinical trials: A qualitative study.

Authors:  Mariana Arevalo; Natalia I Heredia; Sarah Krasny; Maria L Rangel; Leticia A Gatus; Lorna H McNeill; Maria E Fernandez
Journal:  Contemp Clin Trials Commun       Date:  2016-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.